OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients

Open Label Assessment of Long-Term Safety and Utility

NCT00904449 ·Status: COMPLETED ·Phase: PHASE3

Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients

NCT00842829 ·Status: TERMINATED ·Phase: PHASE4

Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain

NCT00458510 ·Status: COMPLETED ·Phase: PHASE3

Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain

NCT00911261 ·Status: COMPLETED ·Phase: PHASE3

Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients

NCT03895762 ·Status: COMPLETED

Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids

NCT00589823 ·Status: COMPLETED ·Phase: PHASE3

Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy

NCT00904280 ·Status: COMPLETED ·Phase: PHASE3

Intranasal Fentanyl for the Treatment of Breakthrough Pain in Cancer Patients (FT-017-IM)

NCT00345735 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer

NCT01842893 ·Status: COMPLETED ·Phase: PHASE3

Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients

NCT00263575 ·Status: COMPLETED ·Phase: PHASE3

Safety of Fentanyl TAIFUN Treatment

NCT00822614 ·Status: UNKNOWN ·Phase: PHASE3

Nasal Fentanyl for Patient Controlled Treatment of Pain in Cancer

NCT01248611 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Fentanyl Matrix Application for Cancer Pain: Multicenter, Prospective, Observational Study

NCT01816503 ·Status: COMPLETED

Efficacy and Safety of Intranasal Fentanyl in the Treatment of Breakthrough Pain (FT-018-IM)

NCT00362583 ·Status: COMPLETED ·Phase: PHASE3

Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer Patients

NCT03809455 ·Status: WITHDRAWN ·Phase: PHASE2

Optimizing Subcutaneous FEntanyl titRation: RApid Achievement of Adequate Exposure When Treating Cancer-Related paIn.

NCT06498037 ·Status: RECRUITING ·Phase: PHASE4

3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain

NCT05265052 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain

NCT00236145 ·Status: COMPLETED ·Phase: PHASE3

Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain

NCT00538863 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Safety and Effectiveness of Fentanyl-TTS Compared to Weak Opioids in Patients With Moderate to Severe Chronic Cancer Pain Previously Treated With NSAIDS (Non-steroidal Anti-inflammatory Drugs).

NCT00576017 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain

NCT00225797 ·Status: COMPLETED ·Phase: PHASE3

Efficacy of Injectable Fentanyl in Sublingual Route Versus Oral Morphine Syrup for Breakthrough Pain

NCT05037539 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Observational Registry Study of Quality of Life When Treating BTcP With Abstral

NCT01936636 ·Status: COMPLETED

Oral Piroxicam Versus Buccal Fentanyl in Breakthrough Pain

NCT02382653 ·Status: COMPLETED ·Phase: NA

Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects

NCT00293033 ·Status: COMPLETED ·Phase: PHASE3